Mechanistically, TRIB3‐amplified NF‐κB signaling upregulates CXCR1/2 ligands in hepatoma cells, attracting neutrophils that enhance EMT via the OSM‐STAT3 pathway, thereby diminishing sorafenib's efficacy. The gene discussed is CXCR1; the disease is hepatocellular carcinoma.